Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Cyclophosphamide, Doxorubicin, and Prednisone in patients with Mycosis Fungoides.

Statements

Source and description
Adcetris (brentuximab vedotin) [product monograph]. HC. Health Canada approved brentuximab vedotin for the treatment of adult patients with CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.